Intellectual Property Management (IPR)

Intellectual Property Management in Pharma: Strategies to Protect Innovation

Intellectual Property in pharmaceuticals refers to the legal rights granted to inventors and companies over the creation of new drugs, processes, dosage forms, or branding elements. Key types of IP…

IP Risks and Patent Conflicts? IPR Management Solutions in Pharma

Identifying symptoms or signals of IPR-related problems starts with vigilant monitoring of production, research, and development environments. Some common signals indicative of potential IPR conflicts may include:Click to read the…

Data exclusivity lapse risk during development – business and regulatory impact analysis

The first step in investigating data exclusivity lapse risks is recognizing symptoms or signals that may indicate potential issues. These could arise from several areas across the pharmaceutical development lifecycle.…

Partner IP obligations missed during development – documentation expectations for audits

Symptoms of missed partner IP obligations can manifest in various ways, often leading to audit findings and compliance issues. Key indicators may include:Click to read the full article.

IP risks during tech transfer during commercialization – preventing repeat IP exposure

Recognizing symptoms that indicate potential IP risks during tech transfer is paramount. Common signs include:Click to read the full article.

Freedom-to-operate gaps during due diligence – preventing repeat IP exposure

Recognizing initial signs of potential FTO gaps is critical in mitigating risk and ensuring compliance. Common symptoms that might indicate an FTO issue during the due diligence process can manifest…

IP risks during tech transfer during lifecycle management – business and regulatory impact analysis

Recognizing the initial symptoms or signals of IP risks is fundamental to addressing potential issues effectively. Here are some common indicators that IP-related risks may be emerging during tech transfers:Click…

Data exclusivity lapse risk during commercialization – risk mitigation and governance actions

The first step in identifying a risk of data exclusivity lapse is recognizing the symptoms or signals on the production floor or in laboratory results. These signals can emerge from…

Data exclusivity lapse risk during lifecycle management – preventing repeat IP exposure

The first step in addressing the data exclusivity lapse risk is identifying the symptoms or signals that indicate a potential issue. These can manifest in various forms, including:Click to read…

IP risks during tech transfer during development – preventing repeat IP exposure

Identifying symptoms or signals of IP risks during a tech transfer is the first step toward mitigating potential fallout. Common indicators may include:Click to read the full article.

Data exclusivity lapse risk during development – risk mitigation and governance actions

Managing Data Exclusivity Lapse Risks During Development: A Structured Investigation Approach In the highly regulated pharmaceutical industry, the lapses in data exclusivity during product development pose significant risks, not only…

Confidentiality breach during partnership discussions – CAPA for IP control weaknesses

Identifying symptoms or signals of a potential confidentiality breach is crucial. These indicators can manifest in various forms: Click to read the full article.